The economic impact of rapid Candida species identification by T2Candida among high-risk patients

Future Microbiology

Volumn 10, Issue 7, 2015, Pages 1133-1144

  Bilir, Sara Pinar ^a   Ferrufino, Cheryl P ^a   Pfaller, Michael A ^b,c   Munakata, Julie ^a  

^a IQVIA   (United States)

^b T2 Biosystems   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

budget impact; candidemia; cost effectiveness analysis; economic model; hospital acquired infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE; DIAGNOSTIC KIT;

ADULT; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DECISION TREE; DIAGNOSTIC TEST ACCURACY STUDY; ECONOMIC ASPECT; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; PICHIA KUDRIAVZEVII; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECIES IDENTIFICATION; CLASSIFICATION; COST BENEFIT ANALYSIS; DIAGNOSTIC KIT; ECONOMICS; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; RISK;

CANDIDA; CANDIDEMIA; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HOSPITAL COSTS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOLOGICAL TYPING TECHNIQUES; REAGENT KITS, DIAGNOSTIC; RISK;

EID: 84938629222     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.29     Document Type: Article

References (36)

1. Ostrosky-Zeichner L, Sable C, Sobel J, et a.l. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26, 271-276 (2007
2. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann. Intensive Care 1, 37 (2011
3. Garey KW, Rege M, Pai MP, et a.l. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43, 25-31 (2006
4. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49, 3640-3645 (2005
5. Arnold HM, Micek ST, Shorr AF, et a.l. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30, 361-368 (2010
6. Valerio M, Rodriguez-Gonzalez CG, Munoz P, et a.l. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J. Antimicrob. Chemother. 69, 1993-1999 (2014
7. Riedel S, Eisinger SW, Dam L, et a.l. Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. J. Clin. Microbiol. 49, 1524-1529 (2011
8. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125, S3-S13 (2012
9. Fernandez J, Erstad BL, Petty W, et a.l. Time to positive culture and identification for Candida blood stream infections. Diagn. Microbiol. Infect. Dis. 64, 402-407 (2009
10. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27, 781-788 (1998
11. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin. Infect. Dis. 43, S15-S27 (2006
12. Neely LA, Audeh M, Phung NA, et a.l. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia. Whole Blood Sci. Transl. Med. 5, 182ra54 (2013
13. Medical Consumer Price Index. www.economagic.com
14. Mauskopf JA, Sullivan SD, Annemans L, et a.l. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 10, 336-347 (2007
15. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et a.l. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin. Infect. Dis. 60, 892-899 (2015
16. Zhao Y, Encinosa W. The Costs of End-of-Life Hospitalizations, 2007: Statistical Brief #81. www.hcup-us.ahrq.gov
17. Healthcare Utilization Project. National Inpatient Sample. www.hcup-us.ahrq.gov
18. Aitken SL, Beyda ND, Shah DN, et a.l. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann. Pharmacother. 48, 683-690 (2014
19. Pfaller MA, Moet GJ, Messer SA, et a.l. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55, 561-566 (2011
20. Pfaller MA, Neofytos D, Diekema D, et a.l. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) Registry, 2004-2008. Diagn. Microbiol. Infect. Dis. 74, 323-331 (2012
21. Golan Y, Wolf MP, Pauker SG, et a.l. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann. Intern. Med. 143, 857-869 (2005
22. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit. Care Med. 33, 1266-1271 (2005
23. Medispan PriceRx. Wolters Kluwer. http://pricerx.medispan.com
24. Pappas PG, Kauffman CA, Andes D, et a.l. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009
25. Clancy CJ, Nguyen MH. Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin. Infect. Dis. 56, 1284-1292 (2013
26. Beyda ND, Alam MJ, Garey KW. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn. Microbiol. Infect. Dis. 77, 324-326 (2013
27. Alexander BD, Johnson MD, Pfeiffer CD, et a.l. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56, 1724-1732 (2013
28. Garey KW, Pai MP, Suda KJ, et a.l. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol. Drug Saf. 16, 919-927 (2007
29. Kollef M, Micek S, Hampton N, et a.l. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin. Infect. Dis. 54, 1739-1746 (2012
30. Zaoutis TE, Argon J, Chu J, et a.l. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41, 1232-1239 (2005
31. Caliendo AM, Gilbert DN, Ginnochio CC, et a.l. Better tests, better care: Improved diagnostics for infectious diseases. Clin. Infect. Dis. 57, S139-S170 (2013
32. Diekema DJ, Pfaller MA. Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin. Infect. Dis. 56, 1614-1620 (2013
33. Holtzman C, Whitney D, Barlam T, Miller NS. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization for rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. J. Clin. Microbiol. 49, 1581-1582 (2011
34. Cleveland AA, Farley MM, Harrison LH, et a.l. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55, 1352-1361 (2012
35. Pfaller MA, Jones RN, Castanheira M. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a six-year period, 2006-2011. Mycoses 57, 602-611 (2014
36. Pfaller MA, Andes DR, Diekema DJ, et a.l. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2, 496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS ONE 9, e101510 (2014